22-Oct-2026 - The Globe and Mail Barclays Reaffirms Their Buy Rating on AbbVie (ABBV) In a report released today, Emily Field from Barclays maintained a Buy rating on AbbVie, with a price target of $325.00. According to TipRanks, Field is a 3-star analyst with an average return of 1.9% ...
20-Oct-2026 - The Globe and Mail Canaccord Genuity Remains a Buy on AbbVie (ABBV) Canaccord Genuity analyst Gary Nachman reiterated a Buy rating on AbbVie today and set a price target of $290.00. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals ...
20-Oct-2026 - The Globe and Mail Citi Sticks to Their Hold Rating for AbbVie (ABBV) In a report released today, Geoff Meacham from Citi maintained a Hold rating on AbbVie, with a price target of $260.00. According to TipRanks, Meacham is a 5-star analyst with an average return of 13.
22-Oct-2026 - The Globe and Mail Barclays Reaffirms Their Buy Rating on AbbVie (ABBV) In a report released today, Emily Field from Barclays maintained a Buy rating on AbbVie, with a price target of $325.00. According to TipRanks, Field is a 3-star analyst with an average return of 1.9% ...
20-Oct-2026 - The Globe and Mail Canaccord Genuity Remains a Buy on AbbVie (ABBV) Canaccord Genuity analyst Gary Nachman reiterated a Buy rating on AbbVie today and set a price target of $290.00. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals ...
20-Oct-2026 - The Globe and Mail Citi Sticks to Their Hold Rating for AbbVie (ABBV) In a report released today, Geoff Meacham from Citi maintained a Hold rating on AbbVie, with a price target of $260.00. According to TipRanks, Meacham is a 5-star analyst with an average return of 13.
